Wyndly Analysis: $2M Raised
What is Wyndly?
Wyndly offers personalized sublingual immunotherapy for allergy sufferers, enabling them to retrain their immune systems at home without allergy shots.
Employees
10
Founded
2020
Revenue
$0-5M
ZoomInfo
Product Features & Capabilities
- personalized sublingual immunotherapy treatment plans, no allergy shots required, FDA-approved sublingual tablets, dedicated board-certified doctor support, medication delivered to your doorstep, allergy testing for 40+ allergens, money-back guarantee if no relief in three months
Pricing
- $100 per month for treatment subscription
- 6-month membership: $600
- Annual membership: $1100 (savings of $100)
- One-time fee for allergy testing: $99
- Unlimited doctor visits and medications included in membership
How much Wyndly raised
1 - $2 million
January 15, 2025Lead Investor: Y Combinator, Goodwater Capital
Who are the founders of Wyndly
AS
Aakash Shah
CEO
MS
Manan Shah
Chief Medical Officer
Competitors Overview
Wyndly's main competitors in the allergy treatment market are Curex and Quello. Here are the notable differences and advantages of each:
- Curex:
- Insurance Acceptance: Curex is the only online allergy clinic that accepts insurance, which can significantly reduce out-of-pocket costs fo
Market Focus
Wyndly primarily focuses on the healthcare industry, specifically in the field of allergy treatment through personalized sublingual immunotherapy.
Investors
- Y Combinator
- Goodwater Capital
- Civilization Ventures
- Sweater Ventures
- Kevin Mahaffey
- Cashmere Fund
- Immeasurable
- Underdog Labs
Business Model
Revenue from at-home allergy tests and personalized treatment plans delivered via subscription model.
See something that needs updating? Suggest edits to this profile.